CliffBio

Alnylam Pharmaceuticals

Patent cliffs & loss of exclusivity

A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.

Company

AngelList URLhttps://angel.co/alnylam-pharmaceuticals
CAGE Code45SR1
Legal NameAlnylam Pharmaceuticals, Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/alnylam-pharmaceuticals
Email format{f}{last}
Facebook URLhttps://www.facebook.com/OUTBio/
Fax Number617.551.8101

4 upcoming patent cliffs

DrugIngredientTypeCliff
  1. GIVLAARIGIVOSIRAN SODIUMSmall mol.Oct 2034
  2. ONPATTROPATISIRAN SODIUMSmall mol.Aug 2035
  3. AMVUTTRAVUTRISIRAN SODIUMSmall mol.Jul 2036
  4. OXLUMOLUMASIRAN SODIUMSmall mol.Nov 2038

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.